1. Home
  2. MTX vs DVAX Comparison

MTX vs DVAX Comparison

Compare MTX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerals Technologies Inc.

MTX

Minerals Technologies Inc.

HOLD

Current Price

$67.59

Market Cap

2.0B

Sector

Industrials

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.63

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTX
DVAX
Founded
1968
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
1992
2004

Fundamental Metrics

Financial Performance
Metric
MTX
DVAX
Price
$67.59
$15.63
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$79.67
$26.50
AVG Volume (30 Days)
167.2K
5.6M
Earning Date
01-29-2026
02-19-2026
Dividend Yield
0.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,071,200,000.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
$4.02
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.73
52 Week Low
$49.54
$9.20
52 Week High
$78.23
$15.73

Technical Indicators

Market Signals
Indicator
MTX
DVAX
Relative Strength Index (RSI) 72.08 85.75
Support Level $65.82 $15.57
Resistance Level $68.24 $15.73
Average True Range (ATR) 1.59 0.06
MACD 0.40 -0.05
Stochastic Oscillator 87.42 70.83

Price Performance

Historical Comparison
MTX
DVAX

About MTX Minerals Technologies Inc.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: